Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing

Microbiology and Immunology

Volumn 47, Issue 7, 2003, Pages 499-505

  Ibe, Shiro ^a   Hotta, Naoe ^a   Takeo, Uta ^a   Tawada, Yukio ^a   Mamiya, Naoto ^a   Yamanaka, Katsuo ^a   Utsumi, Makoto ^a   Kaneda, Tsuguhiro ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Drug resistant HIV 1; Genotype testing; Therapy naive patients

Indexed keywords

EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; DRUG RESISTANCE TEST; DRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS 1; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPAN; LABORATORY TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT; PREVALENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY NAIVE PATIENT; VIRUS INHIBITION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0041309842     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2003.tb03411.x     Document Type: Article

References (19)

1. Alexander, C.S., Dong, W., Chan, K., Jahnke, N., O'Shaughnessy, M.V., Mo, T., Piaseczny, M.A., Montaner, J.S., and Harrigan, P.R. 2001. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 15: 601-607.
2. Boden, D., Hurley, A., Zhang, L., Cao, Y., Guo, Y., Jones, E., Tsay, J., Ip, J., Farthing, C., Limoli, K., Parkin, N., and Markowitz, M. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282: 1135-1141.
3. Bossi, P., Mouroux, M., Yvon, A., Bricaire, F., Agut, H., Huraux, J.M., Katlama, C., and Calvez, V. 1999. Polymorphism of the human immunodeficiency virus type I (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. J. Clin. Microbiol. 37: 2910-2912.
4. Descamps, D., Calvez, V., Izopet, J., Buffet-Janvresse, C., Schmuck, A., Colson, P., Ruffault, A., Maillard, A., Masquelier, B., Cottalorda, J., Harzic, M., Brun-Vézinet, F., and Costagliola, D. 2001. Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study. AIDS 15: 1777-1782.
5. Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., and Lamarre, D. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70: 3763-3769.
6. Hammer, S.M., Squires, K.E., Hughes, M.D., Grimes, J.M., Demeter, L.M., Currier, J.S., Eron, J.J., Jr., Feinberg, J.E., Balfour, H.H., Jr., Deyton, L.R., Chodakewitz, J.A., and Fischl, M.A. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337: 725-733.
7. Hirsch, M.S., Brun-Vézinet, F., D'Aquila, R.T., Hammer, S.M., Johnson, V.A., Kuritzkes, D.R., Loveday, C., Mellors, J.W., Clotet, B., Conway, B., Demeter, L.M., Vella, S., Jacobsen, D.M., and Richman, D.D. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283: 2417-2426.
8. pol genes under highly active antiretroviral therapy. Microbiol. Immunol. 47: 71-79.
9. Leitner, T., Korber, K., Robertson, D., Gao, F., and Hahn, B. 1997. Updated proposal of reference sequences of HIV-1 genetic subtypes, p. III-19-24. In Korber, B., Hahn, B., Foley, B., Mellors, J.W., Leitner, T., Myers, G., McCutchan, F., and Kuiken, C.L. (eds), Human retroviruses and AIDS 1997, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
10. Little, S.J., Holte, S., Routy, J.P., Daar, E.S., Markowitz, M., Collier, A.C., Koup, R.A., Mellors, J.W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J.M., Hellmann, N,S., and Richman, D.D. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347: 385-394.
11. Montaner, J.S., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M.A., Smith, D., Robinson, P., Hall, D., Myers, M., and Lange, J.M. 1998. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279: 930-937.
12. Ou, C.Y., Takebe, Y., Weniger, B.G., Luo, C.C., Kalish, M.L., Auwanit, W., Yamazaki, S., Gayle, H.D., Young, N.L., and Schochetman, G. 1993. Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet 341: 1171-1174.
13. Perno, C.F., Cozzi-Lepri, A., Balotta, C., Bertoli, A., Violin, M., Monno, L., Zauli, T., Montroni, M., Ippolito, G., and D'Arminio-Monforte, A. 2002. Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS 16: 619-624.
14. Perno, C.F., Cozzi-Lepri, A., Balotta, C., Forbici, F., Violin, M., Bertoli, A., Facchi, G., Pezzotti, P., Cadeo, G., Tositti, G., Pasquinucci, S., Pauluzzi, S., Scalzini, A., Salassa, B., Vincenti, A., Phillips, A.N., Dianzani, F., Appice, A., Angarano, G., Monno, L., Ippolito, G., Moroni, M., and D'Arminio-Monforte, A. 2001. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J. Infect. Dis. 184: 983-991.
15. Puig, T., Pérez-Olmeda, M., Rubio, A., Ruiz, L., Briones, C., Franco, J.M., Gómez-Cano, M., Stuyver, L., Zamora, L., Alvarez, C., Leal, M., Clotet, B., and Soriano, V. 2000. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS 14: 727-732.
16. Shafer, R.W., Winters, M.A., Palmer, S., and Merigan, T.C. 1998. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Intern. Med. 128: 906-911.
17. Tamalet, C., Pasquier, C., Yahi, N., Colson, P., Poizot-Martin, I., Lepeu, G., Gallais, H., Massip, P., Puel, J., and Izopet, J. 2000. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J. Med. Virol. 61: 181-186.
18. Yerly, S., Kaiser, L., Race, E., Bru, J.P., Clavel, F., and Perrin, L. 1999. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354: 729-733.
19. Zhang, Y.M., Imamichi, H., Imamichi, T., Lane, H.C., Falloon, J., Vasudevachari, M.B., and Salzman, N.P. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71: 6662-6670.